Compare Crispr Therapeutics AG (CRSP) vs Innodata Inc (INOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Innodata Inc — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Innodata Inc trades at $62.04 (market cap $2.10B). The key difference: Crispr Therapeutics AG is far larger — about 2.3× Innodata Inc's market cap, and Innodata Inc is more actively traded (989,493 versus 2,861,747). Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Innodata Inc for 19 Days on average.
| CRSP | INOD | |
|---|---|---|
Market Cap | $4.88B | $2.10B |
Volume | 2,861,747 | 989,493 |
Sector | Health | Technology |
52-Week High | $73.97 | $121.50 |
52-Week Low | $44.34 | $34.45 |
Typical Hold Time | 77 Days | 19 Days |
Enterprise Value | $3.30B | $1.86B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% amid bearish technical signals. The company shows negative profitability with -$581.60M net income and -4,101.26% net margin for 2025, though Q2 2026 EPS beat expectations. Positive analyst sentiment persists with 57.9% buy ratings and $67.83 consensus target. Recent clinical data presentations and CASGEVY commercial progress provide catalysts.
The stock faces fundamental challenges with persistent losses and negative cash flow from operations, but maintains Wall Street support for its gene-editing pipeline. Key risks include clinical trial outcomes and cash burn, while potential upside hinges on successful drug commercialization and upcoming data readouts through 2026.
INOD is trading at $61.20, down 3.49% today, showing bearish technical signals despite strong fundamental performance. The company has consistently beaten earnings expectations in recent quarters with Q1 2026 EPS of $0.42 versus $0.13 expected. Revenue growth accelerated from $252M in 2025 to $317M in 2026, while net profit margins improved from 12.78% to 14.65%. Recent developments include the opening of a motion-capture AI lab and board appointments strengthening cybersecurity expertise.
The stock presents a growth opportunity with strong AI data engineering positioning and expanding margins, but faces headwinds from premium valuation (P/E 47.43) and technical weakness. Key risks include customer concentration and competitive pressures in the AI services sector. Analyst consensus remains bullish with 4 buy ratings versus 2 holds, suggesting potential upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Innodata Inc
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →
